ABAB Pedia

Steve Chapman

Steve Chapman, named Steven Chapman in company filings, is a biotechnology executive who began in human genetics research at UCLA and joined Genzyme Genetics in 2003. At Natera he led sales, commercial operations and company operations, served as CEO from January 2019 to November 2026, then became a consultant to the company and an adviser to its board.

Contents7 sections
Key facts

UCLA and Genzyme Genetics

Chapman graduated with honors from UCLA in 2002 with a bachelor’s degree in microbiology, immunology and molecular genetics. He began his career in UCLA’s human genetics department researching genetic variation associated with multiple sclerosis. From 2003 to 2010 he worked at Genzyme Genetics.⁠[1][2]

Joining Natera and leading its commercial operations

Chapman joined Natera in December 2010 and held roles including vice president of sales and vice president of commercial operations. He recalled being approximately the twentieth employee. In 2011 he hired his eventual successor, Solomon Moshkevich. He became chief commercial officer in March 2017 and chief operating officer in July.⁠[2][3][4]

Chief executive of Natera

On January 2, 2019, Natera named the 40-year-old Chapman CEO and president. He joined the board that month. Under his leadership the company expanded its women’s health, oncology and organ health businesses. Industry groups recognized him in their 2024 healthcare technology CEO and biotechnology innovation awards. In July 2025 he led Natera in ringing NasdaqNasdaqNasdaq is an exchange operator and financial technology company headquartered in New York. It runs The Nasdaq Stock Market and other markets and provides capital markets technology, regulatory technology, and data and index services. Founded in 1971, it combined with OMX AB in 2008, and in March 2026 the U.S. Securities and Exchange Commission approved its rules for trading tokenized securities.Open the full entry’s opening bell for the tenth anniversary of its listing.⁠[2][5][1][4]

Recalling early sales on Crucible Moments

On Crucible Moments, Chapman recalled that monthly test counts in his first three months went from about 100 to 105 and then down to 90. The decline alarmed the board. Co-founder Jonathan SheenaJonathan SheenaJonathan Sheena is a technology entrepreneur who co-founded PhoneSpots, a mobile technology company, and the genetic testing company Natera. He has served as Natera’s chief technology officer and a director, and as a director of MyOme.Open the full entry reassured him after the meeting, but Chapman went home and told his wife he thought he might be fired. The conversation took place years before he became CEO.⁠[3][6]

Stepping down as CEO

Natera appointed Solomon Moshkevich, its president of clinical diagnostics, as CEO and director effective immediately. It announced that Chapman would continue as a consultant to the company and adviser to the board. Chapman said revenue had grown roughly tenfold during his tenure.⁠[4]

Related Organizations, Websites and Public Accounts

Natera: Former CEO, company consultant and board adviser from November 2026. Official website: https://www.natera.com/ (opens in a new window).⁠[4]

Sources6 sources

  1. Steve Chapman ’02 (opens in a new window)alumni.ucla.edu↑
  2. Natera, Inc. Form 8-K: Appointment of Steven Chapman (opens in a new window)sec.gov↑
  3. Natera ft. Matthew Rabinowitz: A Personal Mission That Led to a Biotech Revolution (opens in a new window)sequoiacap.com↑
  4. Natera Announces Leadership Transition (opens in a new window)natera.com↑
  5. Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year (opens in a new window)investor.natera.com↑
  6. Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution (opens in a new window)youtube.com↑